Acutus Medical Plans Job Cuts; Preliminary Q4, FY21 Sales Exceed Estimates

Acutus Medical Inc AFIB will cut its workforce and implement additional cost reduction measures as a part of corporate restructuring

  • The company expects the actions to result in annualized operating expense savings of $23 million - $25 million compared to 2021. 
  • The company foresees operating expense savings, cost reductions in manufacturing operations, and working capital improvements to result in a 30-40% reduction in quarterly cash burn exiting 2022 compared to 2021. 
  • Acutus expects to start realizing the benefit of its restructuring plan starting late Q1 of 2022.
  • The company anticipates Q4 FY21 revenues of approximately $4.2 million - $4.4 million compared to $2.6 million a year ago and the consensus of $3.99 million.
  • For FY21, the company expects sales of $17.1 million -$17.3 million (vs. the consensus of $16.91 million) compared to $8.5 million for FY20. The company's previous FY21 sales guidance was $17.0 million - $17.5 million.
  • The company noted year-over-year growth in Q4 and FY21 was driven by increased procedure volumes, new product adoption, and higher capital sales.
  • Management continues to view the current COVID-19 situation as being fluid.
  • Price Action: AFIB shares traded higher by 2.04% at $2.58 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!